No current GLP-1 label lists PCOS as an approved use, so prescribing one for it would be off-label. Meta-analysis of 11 randomized trials (GLP-1s): Added to other treatment, GLP-1s lowered BMI by 1.38 kg/m2 (low certainty). The authors found the evidence insufficient on glucose, insulin, hirsutism and menstrual regularity, and call the weight loss modest and short term. ClinicalTrials.gov lists 33 trials of these medicines on it: 6 with posted results and 5 recruiting now.
Read from the registry and PubMed every day. The newest update here is Oct 15, 2026.
Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.
GLP-1s · Mixed · Meta-analysis
Added to other treatment, GLP-1s lowered BMI by 1.38 kg/m2 (low certainty). The authors found the evidence insufficient on glucose, insulin, hirsutism and menstrual regularity, and call the weight loss modest and short term.
A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.
| Medicine | Trials | Posted results | Recruiting |
|---|---|---|---|
| Liraglutide | 14 | 3 | 1 |
| Semaglutide | 8 | 1 | 2 |
| Exenatide | 7 | 2 | 0 |
| Tirzepatide | 2 | 0 | 2 |
| Dulaglutide | 1 | 0 | 0 |
| Mazdutide | 1 | 0 | 0 |
Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.
| Trial | Medicine | Phase | People | Result |
|---|---|---|---|---|
| NCT02635386EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) | Exenatide | Phase 3 | 119 | Oral Disposition (Insulin Sensitivity-insulin Secretion) Index (index score), 24 weeks of treatment. Exenatide Once Weekly (EQW ): 471; Dapagliflozin (DAPA): 311; EQW Plus DAPA: 503; Dapagliflozin Plus Glucophage (MET ER): 395; Phentermine /Topiramate (PHEN/ TPM) ER: 545. |
| APPLELiver and Fat Regulation in Overweight Adolescent Girls | Exenatide | Phase 2/3 | 92 | Hepatic Glucose Release (mg/kg/min), Measured up to 4 months from enrollment. Control: 1.85; PCOS Medication Naive: 1.46; PCOS, Medication Naive + Byetta: 1.54; PCOS on COCPs: 1.88; PCOS on Metformin: 1.57. |
| SAXAPCOSLiraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS | Liraglutide | Phase 3 | 88 | Absolute Body Weight (BW) (kilogram), 32 weeks of treatment. Liraglutide Pen Injector (Saxenda): 104.7; Placebo Liraglutide Pen Injector: 117.9. |
| TEALTreating PCOS With Semaglutide vs Active Lifestyle Intervention | Semaglutide | Phase 2/3 | 60 | Change in Hepatic Fat Fraction (Change in percentage of liver fat), Baseline and 12 weeks. Diet Intervention: -1.41; GLP-1 Intervention: -1.84. |
| LIPTLIPT - Liraglutide in Polycystic Ovary Syndrome | Liraglutide | Phase 4 | 72 | Change in Endogenous Thrombin Potential (ETP) (nMolar x minutes), at time 0 and 26 weeks. Liraglutide: -56.7; Placebo: -8.2. |
| NCT03151005The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS | Liraglutide | Phase 4 | 70 | Assessment of Reproductive Functions (mIU/ml), 12 weeks. Metformin-GLP-1 Receptor Agonist: 5.52; Metformin-Oral Contraceptive(OC): 5.33. |
The registry page names each site and who can enroll. Ask your clinician before joining one.
| Trial | Medicine | Phase | Expected to finish |
|---|---|---|---|
| Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome | Semaglutide | Phase 3 | Jun 30, 2028 |
| Liraglutide Treatment in Obese Infertile PCOS Women | Liraglutide | Phase 4 | Dec 31, 2029 |
| A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese | Tirzepatide | Phase 4 | Dec 2029 |
| Glucagon-Like Peptide-1 Receptor Agonist in ADPKD | Tirzepatide | Phase 2 | Jun 30, 2029 |
| Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS) | Semaglutide | Not phased | Dec 2026 |
Meta-analysis · Eur J Obstet Gynecol Reprod Biol · Oct 15, 2026 · Kar E et al.
Meta-analysis · Front Endocrinol (Lausanne) · Jul 20, 2026 · Omarion A et al.
Meta-analysis · Front Endocrinol (Lausanne) · Jul 3, 2026 · Omarion A et al.
Randomized trial · Diabetes Obes Metab · Jun 3, 2026 · Yang Z et al. · cited by 2
Meta-analysis · Cureus · Apr 9, 2026 · Buragohain S et al. · cited by 1
Meta-analysis · Eur J Endocrinol · Mar 1, 2026 · Forslund M et al. · cited by 1
Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.
Written from each source's own record as it changes. Every change on GLPcompare
Meta-analysis of 11 randomized trials (GLP-1s): Added to other treatment, GLP-1s lowered BMI by 1.38 kg/m2 (low certainty). The authors found the evidence insufficient on glucose, insulin, hirsutism and menstrual regularity, and call the weight loss modest and short term.
Not in any current label we read. A prescriber can still use a medicine off-label, but insurance often limits coverage to approved uses, so ask your plan.
Liraglutide, with 14 registered trials on it, then Semaglutide with 8. More trials do not mean better results: read what each posted.
5 trials are recruiting on ClinicalTrials.gov now, listed below with their registry pages, which name each site and who can enroll.